atomoxetine + placebo

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Social Phobia

Conditions

Generalized Social Phobia

Trial Timeline

Nov 1, 2005 → Jul 1, 2008

NCT ID

NCT00260533

About atomoxetine + placebo

atomoxetine + placebo is a phase 2/3 stage product being developed by Eli Lilly for Generalized Social Phobia. The current trial status is completed. This product is registered under clinical trial identifier NCT00260533. Target conditions include Generalized Social Phobia.

What happened to similar drugs?

12 of 20 similar drugs in Generalized Social Phobia were approved

Approved (12) Terminated (3) Active (7)

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Alprazolam (Xanax) + PlaceboRocheApproved

✅Ziprasidone + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00962104	Phase 3	Completed	Aug 1, 2009	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00716274	Approved	Completed	Sep 1, 2008	Jul 1, 2016	Attention Deficit Hyperactivity Disorder
NCT00607919	Approved	Completed	Mar 1, 2008	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00546910	Approved	Completed	Oct 1, 2007	May 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00617201	Phase 2	Completed	Jul 1, 2007	Aug 1, 2011	Substance Abuse
NCT00406354	Approved	Completed	Nov 1, 2006	Jan 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00380692	Approved	Completed	Oct 1, 2006	Oct 1, 2008	Autistic Disorder
NCT00260533	Phase 2/3	Completed	Nov 1, 2005	Jul 1, 2008	Generalized Social Phobia
NCT00191542	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191295	Phase 2/3	Completed	Feb 1, 2005	Sep 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00190957	Approved	Completed	Aug 1, 2004	Jan 1, 2006	ADHD
NCT00386581	Phase 3	Completed	Jul 1, 2004	Feb 1, 2005	Attention Deficit Disorder With Hyperactivity
NCT00611533	Pre-clinical	Completed	May 1, 2004	Apr 1, 2008	Menopause

Competing Products

20 competing products in Generalized Social Phobia

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40
Quetiapine fumarate + Paroxetine	AstraZeneca	Phase 3	40